Bell2Bell Podcast featuring Howard Weisman, CEO and Buzz Woods of PaxMedica, Inc. (Nasdaq: PXMD)

Bell2Bell’s latest podcast features Howard Weisman, Chairman and CEO of PaxMedica, Inc. (Nasdaq: PXMD), along with Buzz Woods from Corporate Communications, who join the podcast to share insights into the biopharmaceutical company's groundbreaking work in novel anti-purinergic drug therapies (APT) for neurologic conditions, primarily Autism Spectrum Disorder (ASD). Explore the comprehensive interview on the Bell2Bell Podcast, where PaxMedica, Inc., a prominent clinical-stage biopharmaceutical firm, provides valuable perspectives on its innovative initiatives and visionary advancements in the sphere of novel anti-purinergic drug therapies. Gain an exclusive understanding of PaxMedica's pioneering efforts in neurology and biopharmaceutical breakthroughs, with a special emphasis on advancements in treating Autism Spectrum Disorder (ASD) and other neurologic conditions, as Howard Weisman, Chairman and CEO, and Buzz Woods from Corporate Communications, offer a compelling overview of the company's recent achievements and future objectives. Join the highly acclaimed host, Bell2Bell's Stuart Smith, and Howard Weisman, Chairman and CEO of PaxMedica, Inc. (Nasdaq: PXMD) and Buzz Woods Corporate Communications, to learn more about the company’s recent milestones and operational goals for the balance of 2023 and beyond.